New call-to-action
New call-to-action
New call-to-action

Clinical trial of modafinil in children

Here is a recent study looking at the use of modafinil, a wake-promoting drug, in children with excessive daytime sleepiness (primarily narcolepsy).

Here is a recent study (link to abstract below) looking at the use of modafinil, a wake-promoting drug, in children with excessive daytime sleepiness (in this study, primarily narcolepsy).

The study was performed at the University of Louisville School of Medicine, and uses doses of 200-600mg/day -(which is higher than what has been anecdotally reported to be effective for children with PWS). Note that there was exacerbation of psychotic symptoms in one child who had a history of hallucinations -- that has been seen before at high doses in those with prior conditions. Overall, modafinil was found to be well tolerated and helpful. This study is consistent with others that continue to show a generally good safety profile.
Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med. 4: 579-82, 2003.

For updated information on PWS clinical trial opportunities and to sign up for a monthly PWS Clinical Trial Alert, visit our PWS Clinical Trials page

PWS Clinical Trials

Topics: Research

Theresa Strong

author-image

Theresa V. Strong, Ph.D., received a B.S. from Rutgers University and a Ph.D. in Medical Genetics from the University of Alabama at Birmingham (UAB). After postdoctoral studies with Dr. Francis Collins at the University of Michigan, she joined the UAB faculty, leading a research lab focused on gene therapy for cancer and directing UAB’s Vector Production Facility. Theresa is one of the founding members of FPWR and has directed FPWR’s grant program since its inception. In 2016, she transitioned to a full-time position as Director of Research Programs at FPWR. She remains an Adjunct Professor in the Department of Genetics at UAB. She and her husband Jim have four children, including a son with PWS.